Hormone · Investigational
Capromorelin (Entyce)
No lawful US pathway
01 · Overview
Capromorelin is a ghrelin receptor agonist (growth hormone secretagogue) that mimics ghrelin by binding the GHS-R1a receptor, which stimulates appetite and growth hormone release (PMID 29468076). It is given as an oral solution.
Its FDA approvals are veterinary: Entyce for appetite stimulation in dogs and Elura for weight loss in cats with chronic kidney disease (PMID 37493940).
02 · Research summary & key findings
The FDA approved capromorelin (Entyce) for appetite stimulation in dogs in May 2016, and in 2020 approved it (Elura) for managing weight loss in cats with chronic kidney disease (PMID 37493940). In a randomized placebo-controlled trial in inappetent dogs, capromorelin improved owner-rated appetite (68.6 vs. 44.6 percent success) and increased body weight (PMID 27859746). It was previously tested in humans: a trial in older adults raised IGF-1, lean body mass, and some physical function measures but also increased insulin resistance indices, and it has no human approval (PMID 19174493).
03 · Regulatory status
Capromorelin (Entyce) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
No lawful pathway today
Capromorelin (Entyce) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 13 FDA-approved compounds in Hormone
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for hormone optimization?
Capromorelin (Entyce) is an investigational compound, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on hormone optimization, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Oral
References
- [1]Effects of an oral growth hormone secretagogue in older adults J Clin Endocrinol Metab, 2009. PMID 19174493
- [2]A Prospective, Randomized, Masked, Placebo-Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite J Vet Intern Med, 2016. PMID 27859746
- [3]Capromorelin: a ghrelin receptor agonist and novel therapy for stimulation of appetite in dogs Vet Med Sci, 2018. PMID 29468076
- [4]Insights on discovery, efficacy, safety and clinical applications of ghrelin receptor agonist capromorelin in veterinary medicine Vet Res Commun, 2024. PMID 37493940
Primary literature
- PubMed: "Capromorelin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Capromorelin"
Registered interventional and observational studies, including status and phase.
- PubChem: "Capromorelin"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Hormone
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.